Genomics based testing of specific chromosomal loci associated to many diseases including cancer has been in practice for decades. With advancement in high throughput DNA sequencing, it is now possible to sequence hundreds of such loci at low cost and low turnaround time. “At Theomics, we have tested and validated a pan cancer multi loci susceptibility panel which in combination with Illumina MiSEQ deep sequencing platform will be able to accurately predict parameters like progressive rate, survival rate, and probable treatment recommendations. We believe this test could be of significant importance in treatment planning for many cancers as mortality rate of cancer patients are high due to treatment outcome rather than cancer aggression. We are expecting the cost for screening one patient / one sample to be as low as $89.”